Activity of beta-lactam beta-lactamase inhibitor combinations against extended spectrum beta-lactamase producing Enterobacteriaceae in urinary isolates

Journal of the College of Physicians and Surgeons Pakistan

Volumn 22, Issue 6, 2012, Pages 358-362

  Afridi, Faisal Iqbal ^a   Farooqi, Badar Jahan ^a  

^a ZIAUDDIN MEDICAL UNIVERSITY   (Pakistan)

Author keywords

Beta lactam; Beta lactamase; Enterobacteriaceae; Extended spectrum beta lactamase; Urinary tract infections

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEPHALOSPORIN DERIVATIVE; PIPERACILLIN PLUS TAZOBACTAM; SULPERAZON;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM DETECTION; BACTERIUM ISOLATE; DISK DIFFUSION; ENTEROBACTER; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; HOSPITAL POLICY; HUMAN; KLEBSIELLA; NONHUMAN; OBSERVATIONAL STUDY; PROTEUS MIRABILIS; URINALYSIS; URINARY TRACT INFECTION;

AMOXICILLIN; ANTI-BACTERIAL AGENTS; BETA-LACTAM RESISTANCE; BETA-LACTAMASES; CEFOPERAZONE; CLAVULANIC ACIDS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; HUMANS; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID; PIPERACILLIN; SENSITIVITY AND SPECIFICITY; SULBACTAM; URINARY TRACT INFECTIONS;

EID: 84864402812     PISSN: 1022386X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. García C, Llamocca LP, García K, Jiménez A, Samalvides F, Gotuzzo E, et al. Knowledge, attitudes and practice survey about antimicrobial resistance and prescribing among physicians in a hospital setting in Lima, Peru. BMC Clin Pharmacol 2011; 11:18.
2. Herindrainy P, Randrianirina F, Ratovoson R, Ratsima Hariniana E, Buisson Y, Genel N, et al. Rectal carriage of extended- spectrum beta-lactamase-producing gram-negative bacilli in community settings in Madagascar. PLoS One 2011; 6:e22738. Epub 2011 Jul 29.
3. Brun-Buisson C, Legrand P, Philippon A, Montravers F, Ansquer M, Duval J. Transferable enzymatic resistance to third- generation cephalosporins during nosocomial outbreak of multi- resistant Klebsiella pneumoniae. Lancet 1987; 2:302-6.
4. Rupp ME, Fey PD. Extended spectrum beta-lactamase (ESBL)- producing Enterobacteriaceae: considerations for diagnosis, prevention and drug treatment. Drugs 2003; 63:353-65.
5. Roshan M, Ikram A, Mirza IA, Malik N, Abbasi SA, Alizai SA. Susceptibility pattern of extended spectrum ß-lactamase producing isolates in various clinical specimens. J Coll Physicians Surg Pak 2011; 21:342-6.
6. McMullan R, Loughrey AC, McCalmont M, Rooney PJ. Clinico- epidemiological features of infections caused by CTX-M type extended spectrum beta-lactamase-producing Escherichia coli in hospitalised patients. J Infect 2007; 54:46-52. Epub 2006 Feb 14.
7. Jabeen K, Zafar A, Hasan R. Frequency and sensitivity pattern of extended spectrum beta-lactamase producing isolates in a tertiary care hospital laboratory of Pakistan. J Pak Med Assoc 2005; 55:436-9.
8. Hafeez R, Aslam M, Mir F, Tahir M, Javaid I, Ajmal AN. Frequency of extended spectrum beta-lactamase producing gram negative bacilli among clinical isolates. Biomedica 2009; 25:112-5.
9. Lan CK, Hsueh PR, Wong WW, Fung CP, Lau YT, Yeung JY, et al. Association of antibiotic utilization measures and reduced incidence of infections with extended-spectrum beta-lactamase- producing organisms. J Microbiol Immunol Infect 2003; 36:182-6.
10. Turnidge J, Bell J, Biedenbach DJ, Jones RN. Pathogen occurrence and antimicrobial resistance trends among urinary tract infection isolates in the Asia-Western Pacific Region: report from the SENTRY Antimicrobial Surveillance Program, 1998-1999. Int J Antimicrob Agents 2002; 20:10-17.
11. Koneman EW, Allen SD, Janda WM, Procop GW, Schreckenberger PC, Woods GI, et al, editors. Color atlas and textbook of diagnostic microbiology. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2006.
12. Livermore DM, Brown DF. Detection of ß-lactamase-mediated resistance. J Antimicrob Chemother 2001; 48:59-64.
13. Clinical and Laboratory Standards Institute (CLSI). Performance standards for antimicrobial susceptibility testing: twentieth informational supplement. Wayne (PA): CLSI; 2010.
14. Barry AL, Jones RN. Criteria for disk susceptibility tests and quality control guidelines for the cefoperazone-sulbactam combination. J Clin Microbiol 1988; 26:13-7.
15. Daoud Z, Hakime N. Prevalence and susceptibility patterns of extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae in a general university hospital in Beirut, Lebanon. Rev Esp Quimioter 2003; 16:233-8.
16. Kanafani ZA, Mehio-Sibai A, Araj GF, Kanaan M, Kanj SS. Epidemiology and risk factors for extended-spectrum beta- lactamase-producing organisms: a case control study at a tertiary care center in Lebanon. Am J Infect Control 2005; 33: 326-32.
17. Pfaller MA, Segreti J. Overview of the epidemiological profile and laboratory detection of extended-spectrum beta- lactamases. Clin Infect Dis 2006; 42:S153-63.
18. Gales AC, Jones RN, Turnidge J, Rennie R, Ramphal R. Characterization of Pseudomonas aeruginosa isolates: occurrence rates, antimicrobial susceptibility patterns, and molecular typing in the global SENTRY Antimicrobial Surveillance Program, 1997-1999. Clin Infect Dis 2001; 32: S146-55.
19. Miller LA, Ratnam K, Payne DJ. Beta-lactamase-inhibitor combinations in the 21st century: current agents and new developments. Curr Opin Pharmacol 2001; 1:451-8.
20. Stratchounski L, Edelstein I, Narezkina A, Edelstein M, Pimkin M. In vitro activity of cefoperazone-sulbactam vs. amoxicillin- clavulanic acid and piperacillin-tazobactam against extended- spectrum ß-lactamases (ESBL)-producing strains of Escherichia coli and Klebsiella pneumoniae. Italy: The 12th European Congress of Clinical Microbiology and Infectious Diseases; 2000.
21. McLaughlin JC, Barry AL, Fuchs PC, Gerlach EH, Hardy DJ, Pfaller MA. In-vitro activity of five ß-lactam/ß-lactamase inhibitor combinations against consecutive isolates of the Enterobacteriaceae and Pseudomonas aeruginosa. J Antimicrob Chemother 1994; 33:223-30.
22. Ingviya N, Hortiwakul R, Chayakul P, Thamjarungwong B. Prevalence and susceptibility pattern of Klebsiella pneumoniae and Escherichia coli producing extended-spectrum beta- lactamases in Songklanagarind Hospital, Thailand. J Infect Dis Antimicrob Agents 2003; 20:127-34.
23. Rybak B, Naumiuk L, Bronk M, Samet A. Activity of beta- lactam/beta-lactamase inhibitor combinations against ESBL producing Entero-bacteriaceae. France: European Congress of Clinical Microbiology and Infectious Diseases; 2006.
24. Alzahrani AJ, Akhtar N. Susceptibility patterns of extended spectrum ß-lactamase (ESBL)-producing Escherichia coli and Klebsiella pneumoniae isolated in a teaching hospital. Pak J Med Res 2005; 44:64-7.
25. Wong-Beringer A. Therapeutic challenges associated with extended-spectrum, beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae. Pharmacotherapy 2001; 21: 583-92.